Johnson & Johnson beat Wall Street estimates for ​second-quarter sales and profit on Wednesday, as strong growth from immunology drug Tremfya ‌and cancer blockbuster Darzalex more than offset erosion from older products and a drop in sales for heart pumps it picked up in its 2022 acquisition of Abiomed.